Intravenous Thrombolysis in Stroke Attributable to Cervical Artery Dissection

DOI Web Site 被引用文献1件
  • Stefan T. Engelter
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Matthieu P. Rutgers
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Florian Hatz
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Dimitrios Georgiadis
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Felix Fluri
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Lucka Sekoranja
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Guido Schwegler
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Felix Müller
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Bruno Weder
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Hakan Sarikaya
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Regina Lüthy
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Marcel Arnold
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Krassen Nedeltchev
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Marc Reichhart
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Heinrich P. Mattle
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Barbara Tettenborn
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Hansjörg J. Hungerbühler
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Roman Sztajzel
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Ralf W. Baumgartner
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Patrik Michel
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.
  • Philippe A. Lyrer
    From the Stroke Units and Departments of Neurology, University Hospitals Basel (S.T.E., F.H., F.F., P.A.L.), Bern (M.A., K.N., H.P.M.), Geneva (L.S., R.S.), Lausanne (M.P.R., M.R., P.M.), and Zurich (D.G., H.S., R.W.B.), Cantonal Hospitals Aarau (G.S., H.J.H.), Thurgau (Muensterlingen; F.M.), St Gallen (B.W., B.T.), and the Department of Internal Medicine Triemli Hospital (Zurich; R.L.), Switzerland.

抄録

<jats:p> <jats:bold> <jats:italic>Background and Purpose—</jats:italic> </jats:bold> Intravenous thrombolysis (IVT) for stroke seems to be beneficial independent of the underlying etiology. Whether this is also true for cervical artery dissection (CAD) is addressed in this study. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods—</jats:italic> </jats:bold> We used the Swiss IVT databank to compare outcome and complications of IVT-treated patients with CAD with IVT-treated patients with other etiologies (non-CAD patients). Main outcome and complication measures were favorable 3-month outcome, intracranial cerebral hemorrhage, and recurrent ischemic stroke. Modified Rankin Scale score ≤1 at 3 months was considered favorable. </jats:p> <jats:p> <jats:bold> <jats:italic>Results—</jats:italic> </jats:bold> Fifty-five (5.2%) of 1062 IVT-treated patients had CAD. Patients with CAD were younger (median age 50 versus 70 years) but had similar median National Institutes of Health Stroke Scale scores (14 versus 13) and time to treatment (152.5 versus 156 minutes) as non-CAD patients. In the CAD group, 36% (20 of 55) had a favorable 3-month outcome compared with 44% (447 of 1007) non-CAD patients (OR, 0.72; 95% CI, 0.41 to 1.26), which was less favorable after adjustment for age, gender, and National Institutes of Health Stroke Scale score (OR, 0.50; 95% CI, 0.27 to 0.95; <jats:italic>P</jats:italic> =0.03). Intracranial cerebral hemorrhages (asymptomatic, symptomatic, fatal) were equally frequent in CAD (14% [7%, 7%, 2%]) and non-CAD patients (14% [9%, 5%, 2%]; <jats:italic>P</jats:italic> =0.99). Recurrent ischemic stroke occurred in 1.8% of patients with CAD and in 3.7% of non-CAD-patients ( <jats:italic>P</jats:italic> =0.71). </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusion—</jats:italic> </jats:bold> IVT-treated patients with CAD do not recover as well as IVT-treated non-CAD patients. However, intracranial bleedings and recurrent ischemic strokes were equally frequent in both groups. They do not account for different outcomes and indicate that IVT should not be excluded in patients who may have CAD. Hemodynamic compromise or frequent tandem occlusions might explain the less favorable outcome of patients with CAD. </jats:p>

収録刊行物

  • Stroke

    Stroke 40 (12), 3772-3776, 2009-12

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ